Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility-Reference-Cited by-同舟云学术

Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility

Published:2003-06 Issue:6 Volume:21 Page:568-573
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Garcı́a-Olmos M.,Parra A.,Garcı́a-Calvo G.,Ponte C.,Giménez M.J.,Aguilar L.,Soriano F.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference23 articles.

1. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada: Canadian Bacterial Surveillance Network;Chen;N. Engl. J. Med.,1999

2. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979–1997);Granizo;J. Antimicrob. Chemother.,2000

3. Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: in vitro pharmacodynamic simulation;Balcabao;Antimicrob. Agents Chemother.,1996

4. Short-term bactericidal activity of amoxicillin and cefotaxime against penicillin-susceptible and -resistant pneumococcal strains: an in vitro pharmacodynamic simulation;Fenoll;J. Chemother.,2000

5. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin;Fuentes;Eur. J. Clin. Microbiol. Infect. Dis.,2000

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construction of novel magnetic nanoparticles for enrichment of benzo(α)pyrene from edible oils followed by HPLC determination;Food Chemistry;2022-08

2. Role of gemifloxacin in community-acquired pneumonia;Expert Review of Anti-infective Therapy;2008-08

3. Gaps in antibiotic development: the postmarketing task;Reviews in Medical Microbiology;2008-01

4. Specific Antibodies, Levofloxacin, and Modulation of Capsule-Associated Virulence in Streptococcus pneumoniae;Antimicrobial Agents and Chemotherapy;2005-07

5. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point;International Journal of Antimicrobial Agents;2005-02